Symbols / INZY
INZY Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-08-05 08:00 | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | — | 52W Low | — |
| Beta | — | Avg Volume | — | Volume | — |
| Target Price | — | Recom | — | Prev Close | — |
| Price | — | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
No analyst ratings or price targets available.
- Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - Yahoo Finance hu, 22 May 2025 07
- The top 10 analysts of 2025, as measured by TipRanks - CNBC Sun, 25 Jan 2026 08
- BioMarin completes acquisition of Inozyme Pharma, triggers delisting from Nasdaq - Investing.com ue, 01 Jul 2025 07
- Dollar Stock Skyrockets 179% On BioMarin Takeover - Investor's Business Daily Fri, 16 May 2025 07
- BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha Mon, 19 May 2025 07
- BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - Yahoo Finance Mon, 19 May 2025 07
- Is INZY a speculative investment - July 2025 Selloffs & Entry Point Confirmation Signals - mfd.ru hu, 12 Feb 2026 03
- BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease - MedCity News Fri, 16 May 2025 07
- StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - GEN - Genetic Engineering and Biotechnology News Sun, 18 May 2025 07
- BioMarin To Acquire Inozyme Pharma For About $270 Mln In Cash - Nasdaq Fri, 16 May 2025 07
- Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks - Yahoo Finance Wed, 13 Nov 2024 08
- Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders - ChartMill Fri, 16 May 2025 07
- Inozyme: A Major Catalyst Is Uncomfortably Far Off (NASDAQ:INZY) - Seeking Alpha Mon, 27 Nov 2023 08
- Weekly Earnings: Is Lennar Corporation being accumulated by smart money - Entry Point & Long Hold Capital Preservation Tips - baoquankhu1.vn ue, 17 Feb 2026 10
- Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data (NASDAQ:INZY) - Seeking Alpha ue, 21 Feb 2023 08
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for INZY
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|